September 2024.
Belong.Life, a leading global provider of AI-powered patient education and support solutions, announced today that the European Society For Medical Oncology (ESMO) has selected Belong.Life’s abstract (FPN 1834P) for a poster presentation at this year’s ESMO conference. The abstract highlights the positive results of a multi-institutional validation of the BelongAI Dave – Cancer Mentor or “Dave,” the company’s health-grade GenAI cancer mentor.
The study included nine senior oncologists – experts in solid and hematological cancers affiliated with various medical centers – who evaluated Dave’s ability to provide support and guidance with relevant information for cancer management. The oncologists assessed Dave’s replies by aligning them with evidence-based medicine and current international guidelines. The AI cancer mentor’s replies received a positive validation of 91.35% for relevant recommendations. Conversely, 45/578 (7.96%) received a negative validation, while only 5/578 (0.86%) graded as not helpful.
“The findings of these expert oncologists indicate that Dave provides valuable and reliable recommendations to patients living with a wide range of cancers,” said Dr. Daniel Vorobiof, renowned oncologist and Chief Medical Director of Belong.Life. “Furthermore, the use of the AI cancer mentor can support oncologists in managing patients on diverse cancer journeys.”
